Objective valuations for financial reporting, tax and management planning purposes.
This article was reproduced and updated from its original publication in Bloomberg Law on June 18, 2020.
The extraordinary uncertainty associated with the current economic environment has increased the importance and complexity of certain tasks conducted by transaction parties and their counsel as part of M&A pre- and post-closing activities.
For example, in the period between contract signing and closing of an M&A transaction, a buyer conducts final due diligence to confirm that no material adverse effect (MAE) or material adverse change (MAC) has occurred in the target's business that has diminished the value of the target, or otherwise created uncertainty about the target's future business prospects to such an extent that the buyer might terminate the deal.
After closing an M&A transaction, it is customary for the parties to attempt to reach agreement on the target's working capital balance as of the closing date and to adjust the purchase price to reflect any significant difference from the estimate used at closing, in the manner prescribed by the purchase and sale agreement. If the parties are unable to reach agreement, M&A agreements typically include a provision that requires the parties to refer the dispute to an independent third-party.
M&A transaction agreements can include contingent consideration, such as an earnout payment contingent on the performance of the acquired business post-close. Earnouts are a common mechanism for the buyer and seller to shift and allocate risk where future performance is uncertain. Under U.S. GAAP and IFRS, for a business combination the fair value of a contingent consideration liability is recognized and measured as of the closing date, and remeasured at each subsequent reporting date until the contingency is resolved. When performance targets are not met, disputes can arise.
Each of these activities can be significantly impacted by an increase in uncertainty about the target’s future performance.
The World Health Organization characterized the COVID-19 virus as a pandemic on March 11, 2020. It is difficult to fully measure, or even describe, the financial and economic disruptions attributable to the pandemic thus far, or to reliably estimate the long-term consequences. The current economic volatility has led to heightened focus on the potential applicability of MAE clauses for any signed transaction that has not yet closed. If COVID-19 has, for example, led to supply chain disruptions or loss of customers for the target, at what point can it reasonably be determined that an MAE has occurred?
Similarly, for closed M&A transactions, the business dislocations attributable to COVID-19 will likely make the post-closing determination of the target's closing working capital a more onerous and potentially disruptive exercise, as there will likely be significant differences between a seller's and a buyer's estimations of the target's accounts receivable and inventory, among other accounts, in the pandemic environment.
Estimating the fair value of an earnout can become more complex due to the incremental uncertainty associated with the pandemic. Also, changes to fair value of an earnout liability as remeasured at a subsequent reporting date are recognized in earnings (U.S. GAAP) or included in profit or loss (IFRS). Therefore, even for transactions that closed prior to 2020 there can be a sizeable financial reporting impact of the pandemic related to the remeasurement of such unresolved contingent consideration. Disputes are also more likely to arise, for example, if the target’s post-close performance suffers due in part to a lack of anticipated investment by the buyer in growth initiatives for the business.
This article outlines the key accounting, financial and economic analyses that parties and counsel to M&A transactions should undertake in this period of unprecedented economic disruption in attempting to resolve MAE and working capital disagreements, to support their litigation or arbitration posture if disagreements can't be resolved through negotiation and to support valuation of contingent consideration for financial reporting purposes.
The issue of COVID-19 serving as a trigger to terminate a transaction under an MAE clause has already engendered significant legal commentary. Most analyses in the U.S. are informed by Vice Chancellor Laster's landmark ruling in the 2018 Akorn, Inc. v. Fresenius Akabi AG decision in Delaware Chancery Court. Akorn, Inc. v. Fresenius Kabi AG, et al., Del. Ch., C.A. No. 2018-0300, Laster, V.C. (Oct. 21, 2018) (Mem. Op.). Akorn is consequential because it represents the first time that the Chancery Court has permitted a buyer to terminate an M&A transaction due to an MAE.
For our purposes, the most noteworthy element of Akorn is that the court upheld Fresenius' claim that an MAE occurred due to two separate events: Akorn's breach of the bringdown representations and warranties concerning its compliance with certain FDA requirements (including with respect to data security) and its failure to remedy these significant deficiencies (the “bring-down representations” MAE); and the sudden and sustained drop in Akorn's business performance following execution of the merger agreement (the “stand-alone” MAE).
In addressing Fresenius' stand-alone MAE claim–i.e., that Akorn's sharp business decline constituted an MAE–Laster deployed a three-part construct:
This analytical framework reaffirms that analyses of alleged MAEs, and associated arguments in negotiation or litigation, are highly dependent on the facts and circumstances of each transaction. The Akorn ruling is significant because, for the first time, it provides an organized approach, or playbook, for conducting the necessary analyses to determine whether an MAE has occurred.
Mindful of the guidance provided in Akorn, and regardless of whether you are assessing your ability to invoke an MAE clause or preparing to contest a claim that a MAE has occurred due to COVID-19, there are at least four quantitative analyses a party to a pending MAE dispute should undertake:
Detailed Historical Financial Analysis of the Target: Analyze the target company's historical results and financial projections to determine the nature, timing and extent of the decline in the target's business in relation to the potential COVID-19 related MAE. It will be important to examine in depth any pre-COVID-19 downturns in determining whether a post-COVID-19 business or financial decline can be persuasively linked to the pandemic.
Industry and Competitor Analysis: Perform detailed industry, competitor and geographic analyses to determine the extent of any disproportionate impact on the target's business due to business or economic disruptions attributable to the pandemic.
Update Short- and Long-Term Forecasts: Revisit short-term and long-term forecasts of the target company to carefully assess the expected duration of the target company's downturn. This will allow for the differentiation between an anticipated short-term reduction and a longer-term adverse effect that more significantly impacts the underlying value of the target's business or the value of the consolidated enterprise to the buyer.
Refreshed Valuation Analysis: Beyond updated forecasts used as cash flow inputs in a discounted cash flow valuation analysis, assess the appropriateness of discount rates used in determining the magnitude of decline in the underlying value of the target company. Whether or not an MAE is found to have occurred, this analysis will better prepare the parties for potential purchase price renegotiations that may bring the transaction to a mutually satisfactory closing.
In sum, while there is no indication that the Akorn decision will lower the bar for buyers to make the difficult case that an MAE has occurred, we should expect an increase in MAE challenges to pending transactions in the COVID-19 environment and a more pronounced quantitative focus by courts in weighing the parties’ arguments. As has historically been the case, disputes regarding MAEs will be very fact-and-circumstances specific, and parties will be better prepared to defend their respective positions by undertaking the analyses described above.
Another customary feature of an M&A transaction–the post-closing determination of the target's closing working capital and making associated purchase price adjustments–will likely become a more challenging exercise due to the COVID-19 pandemic. Working capital disputes can be contentious in the best of times, but in this period of global economic upheaval across national and industry borders, there likely will be an even greater degree of discrepancy between a seller's pre-closing estimate and a buyer's post-closing true-up of working capital.
U.S. GAAP and IFRS provide relevant guidelines to consider when seeking to measure any impact of COVID-19 on a target company's closing balance sheet. They include the following:
Closing working capital is calculated as of the closing date, and under a GAAP or IFRS basis of preparation, is derived from a balance sheet limited to accounting for those conditions that existed at the closing date but which are informed by additional information learned through the date of preparation of the true-up for those conditions. ASC 855 defines these post-balance sheet subsequent events as Type 1.
By contrast, Type 2 subsequent events either inform conditions or are conditions that did not exist at the balance sheet date and, accordingly, do not affect account balances. In today's environment, the date on which COVID-19 became a condition affecting the target company in relation to the transaction closing date will determine the extent of the pandemic's impact on closing working capital, if any.
In addition, ASC 250 (Accounting Changes and Error Corrections) addresses accounting for a change in an accounting estimate, which is routinely treated as a prospective event and is often an issue in working capital disputes involving improper attempts to use hindsight.
Because contingent consideration assets and liabilities are rarely traded and are often structured in unique, highly leveraged ways, they can be challenging to value, even in normal times. The incremental uncertainty associated with the pandemic does not make this valuation task any easier.
The likely pattern of reduced performance in the near term followed by a recovery also has implications for the structuring of contingent consideration arrangements. For example, in normal times we have seen some multi-year earnouts with each year’s targets expressed as a percentage increase in revenues or EBITDA over the prior year. Such an arrangement for a 2020 transaction might provide little incentive to the seller for the first year post-close (because it might be impossible to achieve growth in the current economic environment) or for the second year post-close (because growth targets might be achievable with little effort, due to poor first year performance).
Some of the analyses suggested above to assist with the determination of whether an MAE has occurred are also appropriate steps for the valuation of contingent consideration associated with a current or prior transaction, specifically:
In addition, for contingent consideration that is structured with a non-linear payoff based on a financial metric (for example, a revenue-based earnout with thresholds, caps, tiers or carry-forwards), the typical valuation methodology applied is a real options approach. Such an approach requires information about the full probability distribution of potential outcomes. In normal times a valuation specialist might use an expected case along with an estimate of volatility based on a historical-analysis of comparable companies. However, additional analysis might be appropriate in the current, unusually uncertain environment. For example, identifying scenarios for how the future might evolve and the expected performance of the subject business in those scenarios could provide (a) additional support for the estimate of the expected case projections for the metric of interest and/or (b) an estimate of future volatility that is more closely tied to the facts and circumstances of the current economic environment than the historical volatility that the target or comparable companies have experienced in the recent past.
The result is an improved understanding of the impact of the current environment on purchase price, a rigorous basis for the valuation of the contingent consideration for financial reporting purposes and better support for the contemporaneous understanding of the impact of the pandemic should a dispute arise post-closing.
In the context of M&A transactions, the effects of the pandemic on the parties and the industries and geographies in which they compete will likely add to the complexity of negotiations and disputes relating to the alleged occurrence of an MAE, the process of truing up the target's closing working capital and the valuation of contingent consideration. In this environment, consideration of the unique facts and circumstances of each transaction will be more relevant than ever. M&A transaction participants and practitioners should be especially mindful of the importance of in-depth accounting, financial and economic analyses to support their positions.
Objective valuations for financial reporting, tax and management planning purposes.
Comprehensive transfer pricing advisory covering compliance, planning, controversy and implementation.
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Providing expert analysis and testimony in the context of litigation, arbitration and other commercial disputes.
Local and global compliance expertise for the financial services industry.
Comprehensive AML support for asset managers.
Provides an array of consulting services to alternative investment managers and investors.
Alternative investment valuation for private equity and hedge funds.